Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies-Reference-Cited by-同舟云学术

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

Published:2021-01 Issue:1 Volume:2 Page:100108
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Ou Sai-Hong Ignatius,Fujiwara Yutaka,Shaw Alice T.,Yamamoto Noboru,Nakagawa Kazuhiko,Fan Frank,Hao Yuki,Gao Yanfei,Jänne Pasi A.,Seto Takashi

Funder

Astra Zeneca

Bristol-Myers Squibb

Daiichi Sankyo

Eisai

Lilly

Merck

Merck Sharp & Dohme

Novartis

Pfizer

Roche

Ariad

Ignyta

Astellas

Chugai Pharmaceuticals

AbbVie

Bayer

Boehringer Ingelheim

Kyowa-Hakko Kirin

Takeda Pharmaceuticals

Ono Pharmaceuticals

Janssen Pharma

Merck Sharp & Dohme, Merck

GlaxoSmithKline

Sumitomo Dainippon

A2 Healthcare

Astellas Pharma

Chugai Pharmaceutical

Linical

Ono Pharmaceutical

Taiho Pharmaceutical

Takeda Pharmaceutical

AstraZeneca

Astellas Pharmaceutics

Bayer Yakuhin

Kissei

Loxo Oncology

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference14 articles.

1. Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer;Kazandjian;Oncologist,2016

2. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials [published correction appears in Lancet Oncol. 2020;21:e70] [published correction appears in Lancet Oncol. 2020;21:e341];Drilon;Lancet Oncol,2020

3. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer;Gainor;JCO Precis Oncol,2017

4. Molecular analysis of plasma from patients with ROS1-positive NSCLC;Dagogo-Jack;J Thorac Oncol,2019

5. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models;Katayama;Nat Commun,2019

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study;Journal of Clinical Oncology;2024-08-01

2. Spotlight on the treatment of non‐small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives;International Journal of Cancer;2024-07-03

3. A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases;International Journal of Molecular Sciences;2024-06-26

4. Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors;Cancer Medicine;2024-04

5. Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data;Expert Opinion on Investigational Drugs;2024-01-29